High-dose-rate Brachytherapy as Adjuvant Local rEirradiation for Salvage Treatment of Recurrent breAst cancer (BALESTRA): a retrospective mono-institutional study.
breast cancer recurrence
interstitial HDR brachytherapy
reirradiation
Journal
Journal of contemporary brachytherapy
ISSN: 1689-832X
Titre abrégé: J Contemp Brachytherapy
Pays: Poland
ID NLM: 101506276
Informations de publication
Date de publication:
Jun 2020
Jun 2020
Historique:
received:
03
03
2020
accepted:
13
04
2020
entrez:
23
7
2020
pubmed:
23
7
2020
medline:
23
7
2020
Statut:
ppublish
Résumé
To evaluate clinical results of catheter-based interstitial high-dose-rate (HDR) brachytherapy (BT) as adjuvant treatment in previously irradiated recurrent breast cancer. Between January 2011 and September 2015, 31 consecutive patients with histologically confirmed recurrent breast cancer after conservative surgery and conventional whole breast radiotherapy, were retreated with a second conservative surgical resection and reirradiated with adjuvant interstitial HDR-BT. None of the brachytherapy implant was performed during the quadrantectomy procedure. A dose of 34 Gy in 10 fractions, 2 fractions per day, with a minimal interval of 6 hours was delivered. At the time of the implant, the median age of patients was 59.7 years (range, 39.3-74.9 years). The median time from first treatment until BT for local recurrence was 11.9 years (range, 2.5-27.8 years). The median interval between salvage surgery and BT was 3.6 months (range, 1-8.2 months). No acute epidermitis or soft tissue side effects higher than grade 2 were recorded, with good cosmetic results in all patients. Most of the patients presented grade 1-2 late side effects. Only one patient developed grade 3 liponecrosis. After a median follow-up of 73.7 months (range, 28.8-102.4 months), the overall survival and cancer specific survival were 87.1% and 90.3%, respectively; 5-year local control and 5-year progression-free survival rate were 90.3% and 83.9%, respectively. Our preliminary analysis showed that HDR-BT is a feasible treatment for partial breast reirradiation offering very low complications rate and fast procedure. Higher patients' cohort is warranted in order to define the role of this treatment modality in the breast conservative management of local recurrence.
Identifiants
pubmed: 32695191
doi: 10.5114/jcb.2020.96860
pii: 41147
pmc: PMC7366017
doi:
Types de publication
Journal Article
Langues
eng
Pagination
207-215Informations de copyright
Copyright © 2020 Termedia.
Déclaration de conflit d'intérêts
The authors report no conflict of interest.
Références
Clin Transl Radiat Oncol. 2019 Oct 02;19:116-122
pubmed: 31692702
Int J Radiat Oncol Biol Phys. 2005 Nov 1;63(3):845-51
pubmed: 16199315
Int J Radiat Oncol Biol Phys. 2017 Aug 1;98(5):1028-1035
pubmed: 28721885
Radiology. 2002 Dec;225(3):713-8
pubmed: 12461250
Breast. 2013 Aug;22 Suppl 2:S141-6
pubmed: 24074775
Radiother Oncol. 2015 Jun;115(3):342-8
pubmed: 26104975
Brachytherapy. 2011 May-Jun;10(3):171-7
pubmed: 20685178
Radiat Oncol. 2008 Sep 18;3:28
pubmed: 18801165
J Surg Oncol. 2014 Jul;110(1):62-7
pubmed: 24788689
Brachytherapy. 2018 Jan - Feb;17(1):154-170
pubmed: 29074088
Clin Breast Cancer. 2017 Nov;17(7):493-502
pubmed: 28396099
Brachytherapy. 2012 May-Jun;11(3):163-75
pubmed: 21816686
Lancet. 2011 Nov 12;378(9804):1707-16
pubmed: 22019144
Eur J Surg Oncol. 2017 Aug;43(8):1409-1414
pubmed: 28536053
Br J Surg. 1999 Jan;86(1):84-7
pubmed: 10027366
Int J Radiat Oncol Biol Phys. 1995 Mar 30;31(5):1341-6
pubmed: 7713792
Breast. 2012 Dec;21(6):707-15
pubmed: 23127279
Breast Care (Basel). 2015 Aug;10(4):265-71
pubmed: 26600763
Am J Clin Oncol. 2010 Oct;33(5):427-31
pubmed: 19884802
Brachytherapy. 2014 Sep-Oct;13(5):488-92
pubmed: 24950822
Breast Cancer. 2014 Nov;21(6):754-60
pubmed: 23483442
Brachytherapy. 2008 Jan-Mar;7(1):29-36
pubmed: 18201940
Breast J. 2013 May-Jun;19(3):310-8
pubmed: 23745196
Rep Pract Oncol Radiother. 2017 Jul-Aug;22(4):277-283
pubmed: 28507456
Strahlenther Onkol. 2018 Sep;194(9):806-814
pubmed: 29796694
Ann Oncol. 2007 Mar;18(3):468-72
pubmed: 17158776
BMC Cancer. 2007 Sep 14;7:178
pubmed: 17854511
Clin Adv Hematol Oncol. 2006 Oct;4(10):719-21
pubmed: 17111558
Cancer Treat Rev. 2013 Nov;39(7):737-41
pubmed: 23465859
Eur J Surg Oncol. 2019 Aug;45(8):1317-1327
pubmed: 30795956
Int J Breast Cancer. 2012;2012:571946
pubmed: 23091733
Breast Cancer Res Treat. 2018 Apr;168(3):739-744
pubmed: 29335922
Ann Surg Oncol. 2020 Mar;27(3):752-762
pubmed: 31732946
Ann Surg Oncol. 2012 Nov;19(12):3771-6
pubmed: 22618719
Int J Radiat Oncol Biol Phys. 2002 Jul 1;53(3):687-91
pubmed: 12062613
Radiother Oncol. 2018 Sep;128(3):411-420
pubmed: 29691075
Cancer Radiother. 2018 Jun;22(4):372-381
pubmed: 29859761
Oncology. 2003;64(1):1-6
pubmed: 12457024
Radiother Oncol. 2013 Aug;108(2):226-31
pubmed: 23647758
Breast. 2017 Jun;33:159-165
pubmed: 28395234
Ann Surg Oncol. 2020 May;27(5):1638-1644
pubmed: 31646449
Int J Radiat Oncol Biol Phys. 2006 Feb 1;64(2):489-95
pubmed: 16246495
Brachytherapy. 2011 Jan-Feb;10(1):74-80
pubmed: 20685174
Brachytherapy. 2019 May - Jun;18(3):411-419
pubmed: 30890318
Adv Radiat Oncol. 2017 Feb 28;2(2):176-182
pubmed: 28740929
Lancet Oncol. 2013 Dec;14(13):1269-77
pubmed: 24225155
Ann Surg Oncol. 2010 Jun;17(6):1471-4
pubmed: 20180029
J Contemp Brachytherapy. 2009 Oct;1(3):131-136
pubmed: 27807454
Breast J. 2019 Nov;25(6):1160-1170
pubmed: 31338974
Int J Radiat Oncol Biol Phys. 2008 Feb 1;70(2):477-84
pubmed: 17869019
J Contemp Brachytherapy. 2019 Apr;11(2):101-107
pubmed: 31139217
J Contemp Brachytherapy. 2019 Aug;11(4):312-319
pubmed: 31523231
Int J Radiat Oncol Biol Phys. 2016 Apr 1;94(5):1073-87
pubmed: 26899950
Ann Surg Oncol. 2019 Oct;26(10):3018-3024
pubmed: 31342396
Cancer. 2004 Jun 1;100(11):2269-80
pubmed: 15160329
Strahlenther Onkol. 2016 Apr;192(4):199-208
pubmed: 26931319
Breast Cancer Res. 2005;7(5):R828-32
pubmed: 16168129
Brachytherapy. 2008 Jan-Mar;7(1):22-8
pubmed: 18299110
Strahlenther Onkol. 2006 Feb;182(2):102-7
pubmed: 16447017
Int J Radiat Oncol Biol Phys. 2010 Nov 1;78(3):804-10
pubmed: 20106605
Radiother Oncol. 2012 Jan;102(1):96-101
pubmed: 21907439